NCT06935188: Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC
- State
- Under way
- Phase
- Phase 2
- People
- 98 planned
- Started
- 17 Apr 2025
- Primary completion
- 31 Dec 2028
- Arms
- Dalpicilib combined with cetuximab
- Results
- None posted
- 17 Apr 2025: Trial started
- 20 Apr 2025: Trial registered